Eltivutabart Drug Asset Due Diligence Report 2026

This Eltivutabart Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Eltivutabart can convert its Monoclonal antibody profile and CD39 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Eltivutabart (query alias: Eltivutabart)
Modality / target	Monoclonal antibody; CD39; CD39 inhibitors
Highest global status	Phase 2
Originator	Tizona Therapeutics, Inc.
Active developers	Trishula Therapeutics, Inc., Tizona Therapeutics, Inc.

The MCP disease footprint includes Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Gastrooesophageal junction cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06119217	Phase 2	Completed	194	Primary endpoint not disclosed in English source
NCT04306900	Phase 1	Completed	185	Primary endpoint not disclosed in English source
NCT03884556	Phase 1	Completed	56	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma

Phase 2; n=194; evaluation: Not stated in English source. Reported fields: Progression-free Survival (PFS) - Biomarker Enriched Population(Median) = 5.5 Month (95%CI, 3.7 - 7.3); Progression-free Survival (PFS) - Biomarker Enriched Population(Median) = 7.3 Month (95%CI, 3.6 - 9.7)

659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer

Phase 2; n=59; evaluation: Positive. Reported fields: AE(Grade ≥3) = neutrophil count decreased (41%), neutropenia (22%), anaemia (20%), fatigue (12%) and ALT increased (10%). ; AE(Grade ≥3) = neutrophil count decreased (41%), neutropenia (22%), anaemia (20%), fatigue (12%) and ALT increased (10%).

Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer

Not Applicable; n=not disclosed; evaluation: Not stated in English source. Reported fields: ORR = 61 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Eltivutabart addresses Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Gastrooesophageal junction cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-01-03	AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39	Preclinical	US$105.0M upfront; US$105.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treating pancreatic tumors expressing certain biomarkers”. The milestone feed surfaced a patent-application signal described as “Combinations with an anti human CD39 antibody, an anti human PD-1 antibody, and chemotherapy in gastric cancer”. The milestone feed surfaced a patent-application signal described as “Combination therapy involving Anti-CD39 antibodies and adoptive cell therapy”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO